Informed Prostate Cancer Patient Support

A NOVEL UNBIASED SEED-BASED RNAi SCREEN IDENTIFIES SMALL RNAs THAT INHIBIT ANDROGEN SIGNALING AND PROSTATE CANCER CELL GROWTH | bioRxiv Blocking androgen receptor signaling is the mainstay of therapy for advanced prostate cancer (PCa). However, acquired resistance to single agents targeting this pathway results in the development of lethal castration resistant PCa.  Combination therapy approaches represent a promising strategy for the treatment of advanced disease. Here we explore a therapeutic strategy for PCa based on the ability of sh/siRNAs https://horizondiscovery.com/en/applications/rnai/shrna-applications https://www.news-medical.net/life-sciences/What-is-SiRNA.aspx  to function essentially as miRNAs https://medical-dictionary.thefreedictionary.com/miRNA and, via seed sequence complementarity, induce RNA interference of numerous targets simultaneously.  We developed a library that contained shRNAs with all possible seed sequence combinations to identify those ones that

Long‐term outcomes of radical prostatectomy versus low‐dose‐rate brachytherapy in patients with intermediate‐risk prostate cancer: Propensity score matched comparison - Urabe - The Prostate - Wiley Online Library

Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer - Mustaffa - The Prostate - Wiley Online Library

UCSF Investigators Improve MR-guided TRUS Fusion Biopsy for Prostate Cancer Detection Using HP 13C MRI | UCSF Radiology

(42714) Inoreader - Exosome-derived lncRNA HOXA-AS3 promotes castration resistance and progression of prostate cancer via the miR-29b-3p/Mcl-1/STAT3 axis

Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research

External Beam Radiotherapy With or Without Brachytherapy Boost in Men with Very High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis - ScienceDirect

Active Surveillance 101 - YouTube

External Beam Radiotherapy With or Without Brachytherapy Boost in Men with Very High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis - International Journal of Radiation Oncology, Biology, Physics

Genetically modified herpes virus delivers one-two punch against advanced cancers - The Institute of Cancer Research, London

How prostate cancer may begin -- ScienceDaily sciencedaily.com How prostate cancer may begin 4-5 minutes Researchers at the University of East Anglia have made an important discovery about how prostate cancer may start to develop. A new study published today reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue cells throughout the whole prostate are primed and ready to develop prostate cancer. This means that it may be better to treat the whole prostate rather than only the areas in the prostate that have cancer. The team hope their work could help scientists better understand the causes of prostate cancer, and even prevent it altogether. Lead researcher Prof Daniel Brewer, from UEA's Norwich Medical School, said: "Prostate cancer is the most common cancer in men and kills one man every 45 mi

IRF7 impacts on prostate cancer cell survival in response to radiation | bioRxiv

Tumoroscope: a probabilistic model for mapping cancer clones in tumor tissues | bioRxiv

Researchers identify drug resistance factors for advanced prostate cancer -- ScienceDaily sciencedaily.com Researchers identify drug resistance factors for advanced prostate cancer 4-5 minutes In a new study published in Molecular Cancer Researc h, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer. "We defined a potential strategy for both responders and nonresponders of the drug that may help men overcome resistance and prolong survival," says Liewei Wang, M.D., Ph.D., the Bernard and Edith Waterman Director, Pharmacogenomics Program, Mayo Clinic's Center for Individualized Medicine. Dr. Wang is the corresponding author of the study. Dr. Wang explains that while several drug choices are available to control dis

Two Factors to ID Men at Highest Risk for Prostate Cancer Death medscape.com Two Factors to ID Men at Highest Risk for Prostate Cancer Death Roxanne Nelson, RN, BSN A family history of prostate cancer has long been one of the few universally accepted risk factors for the disease. New findings now provide evidence that risk stratification based on family history and inherited polygenic risk can identify men at highest risk of dying from the disease before age 75 Men in the upper quartile of polygenic risk score or who had a family history of prostate or breast cancer accounted for close to 100% of prostate cancer deaths by age 75. This strategy can also identify men at low risk for prostate cancer, potentially sparing them from intensive prostate cancer screening. "This study provides compelling evidence for integrating a prostate cancer PRS [polygenic risk score] with information on family history of prostate and breast canc

Coffee Might Give Some Men an Edge Battling Prostate Cancer | Cooking with Kathy Man cookwithkathy.wordpress.com Coffee Might Give Some Men an Edge Battling Prostate Cancer Cara Murez wrote . . . . . . . . . For some men battling prostate cancer, drinking coffee may offer not just a quick pick-me-up but longer survival. Research is still in the early phases, but a new study finds an association between a genotype that metabolizes caffeine quickly and longer survival from prostate cancer. That genotype is called CYP1A2 AA. “I’m very excited about this work because each time we’re digging in deeper. I think it has some really interesting findings that say, ‘Hey, there may be something here.’ We need to look more into what could be going on in terms of coffee and impact on people’s lives, and especially those who are diagnosed with cancer,” said lead study author Dr. Justin Gregg. He is a urologic oncologist at the University of Texas MD An

Multi-omics biomarkers aid prostate cancer prognostication | bioRxiv

How are Medicare benefits changing for 2023? medicareresources.org How are Medicare benefits changing for 2023? Louise Norris September 17, 2022 Reviewed by our health policy panel. 16-20 minutes Key takeaways The standard Part B premium is expected to remain at $170.10 for 2023, or possibly decrease . (This won’t be finalized until November 2022.) The Part B deductible is $233 in 2022, and is projected to remain at that level in 2023. Part A premiums, deductible, and coinsurance are projected to increase in 2023 . The income brackets for high-income premium adjustments for Medicare Part B and D start at $91,000 for a single person, but this threshold is expected to increase to $97,000 in 2023. Medicare Advantage enrollment is expected to continue to increase in 2023. The maximum allowable out-of-pocket cap for Medicare Advantage plans is increasing to $8,300 in 2023 (but most plans h

6 Critical Changes To Medicare Drug Plans For 2023 | TravelAwaits travelawaits.com 6 Critical Changes To Medicare Drug Plans For 2023 Nathan Toal, HIA, CPLHI, FFMCSep.20.2022 6-8 minutes Over the past few years, there have been some major improvements to the Medicare system — especially in the pharmaceutical area. One major change was to the fabled and feared “donut-hole.” Even the name was deceiving. Who doesn’t love donut holes?! In celebration of this article, I even had to grab a few this morning. The scary imposter “donut-hole” used to be an area of Medicare pharmaceutical coverage called the Part D Coverage Gap . Pre-2020, the coverage gap would occur when you reached a certain amount set by congress every year. In 2019, it was $3,820. This meant once your Part D paid $3,820, you would essentially lose coverage until you reached the catastrophic stage. This stage would kick in w

Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis - Brodowsky - The Prostate - Wiley Online Library

Shannon Sharpe Reveals 2016 Prostate Cancer Diagnosis, Says He’s Now Cancer-Free – NBC 7 San Diego

Relugolix in the management of prostate cancer: Expert Review of Anticancer Therapy: Vol 22, No 9

UCSF Pilot Award to Help Develop Improved Method for 225Ac Radioimmunotherapy of Prostate Cancer Sep. 18, 2022, 6:00 a.m. University of California's, San Francisco (UCSF) advanced targeted alpha therapy (TAT) agent called 225Ac-DOTA-YS5, can treat prostate cancer while allowing verification of its activity in prostate cancer models, according to Kondapa Naidu Boppa, Ph.D., assistant professional researcher in UCSF’s Department of Radiology and Biomedical Imaging. In the case of the UCSF advancement, the TAT uses radioimmunotherapy, helping to deliver high doses of highly lethal alpha participants to the targeted tumors. At UCSF, thus far, this particular agent has been used to target an antigen highly expressed in prostate cancer known as CD46. Now, UCSF researchers have received a pilot reward to develop further and improve the imaging and therapeutic agent targeting prostate cancer. Specifically, Kondapa Naidu Bobba, and Bin Liu, Ph.D., a professor in the UCSF Depart

The evolving standards of active surveillance monitoring | Prostate Cancer and Prostatic Diseases

New Treatment Turns Cancer Genes Into "Eat Me" Signs For Immune System

Hormonal resistance prostate cancer cells | IJN

Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer | Clinical Cancer Research | American Association for Cancer Research

A Pilot Award to Development an Improved Method for 225Ac Radioimmunotherapy of Prostate Cancer | UCSF Radiology

Treat the mind, not just the body for prostate cancer nature.com Treat the mind, not just the body for prostate cancer Vargas-Parada, Laura The involvement of the prostate gland in sexual function, and the impact of treating tumours in it, make cancer in this part of the body an especially difficult one to deal with psychologically. Miguel Ángel Jiménez-Ríos, a urological oncologist at Mexico’s National Cancer Institute in Mexico City, spoke to Nature about how the psychology of the disease affects screening rates and patients’ quality of life, and how best to address these issues. How does the psychological burden differ from that of other cancers? Prostate cancer affects an organ that is linked to masculinity. Treatment can impair sexual and reproductive functions. We use drugs that block male hormones, but these produce mood and cognitive changes. Other treatments can cause loss of erections, weaker orgasms or incontinence. Som

Research suggests commonly used prostate cancer treatment rewires engine of prostate tumors: Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors -- ScienceDaily sciencedaily.com Research suggests commonly used prostate cancer treatment rewires engine of prostate tumors: Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors 6-8 minutes Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. While successful in most cases, these drugs can eventually stop working, but there is a limited understanding about how this change occurs. A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape

A better way to biopsy in prostate cancer

How to improve the diagnosis of prostate cancer

Metastatic prostate cancer: seeking a fresh chance of recovery

Treat the mind, not just the body for prostate cancer

Researchers take on the challenge of prostate cancer

Prostate cancer: highlights from research

Does prostate-cancer treatment place a strain on the heart?

Could immunotherapy finally break through in prostate cancer?

The destructive power of PROTACs could tackle prostate cancer

Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases | Prostate Cancer and Prostatic Diseases

Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer—exploratory analysis of LATITUDE study | Prostate Cancer and Prostatic Diseases : Pain is an important dimension of quality-of-life in patients with metastatic castrate-sensitive prostate cancer (mCSPC). However, it is unclear if dynamic change in pain over time can predict for overall survival (OS) or radiographic progression-free survival (rPFS) in these patients. This is an exploratory analysis of LATITUDE, a phase III randomized study, in which men with de novo mCSPC were randomized to receive either ADT plus abiraterone versus ADT alone. Information was collected on patient-reported worst pain score (WPS) and pain-interference score (PIS) from the Brief Pain Inventory-Short Form. A Bayesian joint modelling approach was used determine the association of dynamic change in WPS and PIS with OS and rPFS. Overall, 1125 patients with at least 3 measurements on pain scores

Prostate cancer has high survival rate if detected early floridatoday.com Early detection of prostate cancer is key, can have a high survival rate if found in time 6-7 minutes Dr. Mourad Abouelleil Support local journalism.  A digital subscription is incredibly affordable and makes you the most informed person around.  Click here and subscribe today . Prostate cancer is one of the most common cancers found in men. According to Cancer.Net, in 2022, 268,490 men in the United States will be diagnosed with prostate cancer. Around 60% of all cases will be diagnosed in people over the age of 65, but when detected early, there is an overall five- and 10-year survival rate of 98%. Screenings, early detection and advanced treatments are keys to these high survival rates. More health-related articles: Krista on fitness: Want to grow your muscles? Follow this advice and watch yourself get thick Dr. Mitr